Intra-Cellular Therapies, Inc. vs ADMA Biologics, Inc.: SG&A Expense Trends

SG&A Expense Trends: A Tale of Two Biotech Companies

In the competitive world of biotechnology, managing expenses is crucial for growth and sustainability. This analysis highlights the Selling, General, and Administrative (SG&A) expense trends of two prominent players: Intra-Cellular Therapies, Inc. and ADMA Biologics, Inc., from 2014 to 2023.

Intra-Cellular Therapies, Inc.

Over the past decade, Intra-Cellular Therapies has seen a staggering increase in SG&A expenses, growing nearly 40 times from 2014 to 2023. This reflects their aggressive expansion and investment in research and development, crucial for their innovative therapies.

ADMA Biologics, Inc.

ADMA Biologics, on the other hand, has experienced a more modest growth in SG&A expenses, increasing by approximately 12 times over the same period. This steady rise indicates a more conservative approach, focusing on sustainable growth and market penetration.

These trends underscore the diverse strategies employed by biotech firms in navigating the complex landscape of healthcare innovation.